Low molecular weight heparin and radical prostatectomy

A prospective analysis of safety and side effects

Michael Koch, J. A. Smith

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

We prospectively analyzed the safety of the perioperative use of low molecular weight heparin (LMWH) for prophylaxis of thromboembolic complications after radical retropubic prostatectomy (RRP). Seventy-three consecutive patients received Enoxaparin, a LMWH compound one hour before RRP and then every twelve hours until hospital discharge. A mean of seven doses of LMWH were administered. A comparison was made with a control group of eighty-nine patients undergoing RRP without anticoagulant prophylaxis. Estimated blood loss was 515 ± 215 cc with LMWH patients and 611 ± 471 cc in controls. Total drain output was a mean of 318 cc with LMWH and 300 cc in controls. Seven percent of patients treated with enoxaparin developed a wound or operative site hematoma or lymphocele compared with none in the control group. LMWH appears to be a relatively safe means of prophylaxis for thromboembolic complications after RRP with no apparent increase in intraoperative bleeding or postoperative drainage. However, postoperative hemorrhagic complications or lymphocele formation are slightly increased. LMWH should be considered for prophylaxis of thromboembolic complications in high risk individuals but the associated morbidity does not support its routine use.

Original languageEnglish (US)
Pages (from-to)101-104
Number of pages4
JournalProstate Cancer and Prostatic Diseases
Volume1
Issue number2
StatePublished - 1997
Externally publishedYes

Fingerprint

Low Molecular Weight Heparin
Prostatectomy
Safety
Lymphocele
Enoxaparin
Control Groups
Hematoma
Anticoagulants
Drainage
Hemorrhage
Morbidity
Wounds and Injuries

Keywords

  • Heparin
  • Venous thrombosis prophylaxis

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Low molecular weight heparin and radical prostatectomy : A prospective analysis of safety and side effects. / Koch, Michael; Smith, J. A.

In: Prostate Cancer and Prostatic Diseases, Vol. 1, No. 2, 1997, p. 101-104.

Research output: Contribution to journalArticle

@article{5f2180670aeb4e7fb9ea52619604f8e9,
title = "Low molecular weight heparin and radical prostatectomy: A prospective analysis of safety and side effects",
abstract = "We prospectively analyzed the safety of the perioperative use of low molecular weight heparin (LMWH) for prophylaxis of thromboembolic complications after radical retropubic prostatectomy (RRP). Seventy-three consecutive patients received Enoxaparin, a LMWH compound one hour before RRP and then every twelve hours until hospital discharge. A mean of seven doses of LMWH were administered. A comparison was made with a control group of eighty-nine patients undergoing RRP without anticoagulant prophylaxis. Estimated blood loss was 515 ± 215 cc with LMWH patients and 611 ± 471 cc in controls. Total drain output was a mean of 318 cc with LMWH and 300 cc in controls. Seven percent of patients treated with enoxaparin developed a wound or operative site hematoma or lymphocele compared with none in the control group. LMWH appears to be a relatively safe means of prophylaxis for thromboembolic complications after RRP with no apparent increase in intraoperative bleeding or postoperative drainage. However, postoperative hemorrhagic complications or lymphocele formation are slightly increased. LMWH should be considered for prophylaxis of thromboembolic complications in high risk individuals but the associated morbidity does not support its routine use.",
keywords = "Heparin, Venous thrombosis prophylaxis",
author = "Michael Koch and Smith, {J. A.}",
year = "1997",
language = "English (US)",
volume = "1",
pages = "101--104",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Low molecular weight heparin and radical prostatectomy

T2 - A prospective analysis of safety and side effects

AU - Koch, Michael

AU - Smith, J. A.

PY - 1997

Y1 - 1997

N2 - We prospectively analyzed the safety of the perioperative use of low molecular weight heparin (LMWH) for prophylaxis of thromboembolic complications after radical retropubic prostatectomy (RRP). Seventy-three consecutive patients received Enoxaparin, a LMWH compound one hour before RRP and then every twelve hours until hospital discharge. A mean of seven doses of LMWH were administered. A comparison was made with a control group of eighty-nine patients undergoing RRP without anticoagulant prophylaxis. Estimated blood loss was 515 ± 215 cc with LMWH patients and 611 ± 471 cc in controls. Total drain output was a mean of 318 cc with LMWH and 300 cc in controls. Seven percent of patients treated with enoxaparin developed a wound or operative site hematoma or lymphocele compared with none in the control group. LMWH appears to be a relatively safe means of prophylaxis for thromboembolic complications after RRP with no apparent increase in intraoperative bleeding or postoperative drainage. However, postoperative hemorrhagic complications or lymphocele formation are slightly increased. LMWH should be considered for prophylaxis of thromboembolic complications in high risk individuals but the associated morbidity does not support its routine use.

AB - We prospectively analyzed the safety of the perioperative use of low molecular weight heparin (LMWH) for prophylaxis of thromboembolic complications after radical retropubic prostatectomy (RRP). Seventy-three consecutive patients received Enoxaparin, a LMWH compound one hour before RRP and then every twelve hours until hospital discharge. A mean of seven doses of LMWH were administered. A comparison was made with a control group of eighty-nine patients undergoing RRP without anticoagulant prophylaxis. Estimated blood loss was 515 ± 215 cc with LMWH patients and 611 ± 471 cc in controls. Total drain output was a mean of 318 cc with LMWH and 300 cc in controls. Seven percent of patients treated with enoxaparin developed a wound or operative site hematoma or lymphocele compared with none in the control group. LMWH appears to be a relatively safe means of prophylaxis for thromboembolic complications after RRP with no apparent increase in intraoperative bleeding or postoperative drainage. However, postoperative hemorrhagic complications or lymphocele formation are slightly increased. LMWH should be considered for prophylaxis of thromboembolic complications in high risk individuals but the associated morbidity does not support its routine use.

KW - Heparin

KW - Venous thrombosis prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=0001257573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001257573&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 101

EP - 104

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 2

ER -